Kardigan

Kardigan is a private, pre-revenue biotech focused on transforming cardiovascular medicine through a pipeline of late-stage, targeted small molecule therapies. The company has three active clinical programs targeting genetic dilated cardiomyopathy, acute severe hypertension, and calcific aortic stenosis, with recent positive Phase 2 data announced for its hypertension candidate. Led by a seasoned team with a successful exit history, including CEO Tassos Gianakakos who previously led MyoKardia to a $13.1B acquisition, Kardigan combines deep cardiovascular expertise with an AI-enhanced platform to pursue functional cures for major heart diseases.

Integrated 'Cardiac Intelligence' platform combining AI, real-world patient data (via subsidiary Prolaio), and deep cardiovascular expertise to modernize drug discovery, inform clinical trial design, and identify novel targets.

Kardigan competes in the crowded cardiovascular therapeutics space against large pharma (e.g., Novartis, AstraZeneca, Bayer) and other biotechs. Its differentiation lies in its focus on targeted, disease-modifying therapies for specific subpopulations and its integrated data/AI platform. Its leadership's prior success with MyoKardia is a unique competitive asset.